New Stock Issuance - The new stock "同宇新材" (code: 301630) is listed at an issuance price of 84.00[1] - "信通电子" (code: 001388) has an issuance price of 16.42[1] Rights Issues and Announcements - "济川药业" (code: 600566) has a tender offer period from June 18, 2025, to July 17, 2025[1] - "中程退" (code: 300208) has 13 trading days remaining until the last trading day[1] - "退市锦港" (code: 600190) also has 13 trading days remaining until the last trading day[1] - "恒立退" (code: 000622) has 10 trading days remaining until the last trading day[1] Abnormal Fluctuations - "浙江东日" (code: 600113) reported severe abnormal fluctuations[1] - "汇金股份" (code: 300368) is noted for abnormal fluctuations[3]

Group 1 - A-share annual report dividend trend continues, with 198 companies distributing nearly 699 billion yuan this week [1] - China Ping An leads with a dividend of 293.34 billion yuan, followed by China General Nuclear Power and GF Securities with 47.97 billion yuan and 30.42 billion yuan respectively [1] - Over 2875 companies have completed annual report dividends, totaling nearly 977.5 billion yuan, accounting for 59.5% of the total annual dividend amount [1] Group 2 - The Shanghai Stock Exchange announced that cash dividends for Shanghai-listed companies in 2024 are expected to reach 1.8 trillion yuan, a historical high, with a dividend payout ratio of 35.6% [1][27] - Approximately 500 companies are set to issue interim dividends to meet investor cash flow needs [27] - In the past three years, 68 companies have cumulatively distributed over 10 billion yuan in cash dividends, and 872 companies have maintained a dividend payout ratio exceeding 30% for three consecutive years [27] Group 3 - The CSI Dividend ETF (515080) announced a dividend of 0.15 yuan per ten shares, with a distribution ratio of 0.99% [24][26] - This marks the 13th dividend distribution since the ETF's inception, with a cumulative dividend amount of 3.5 yuan per ten shares [26] - The ETF's annual dividend ratios over the past five years have been 4.53%, 4.14%, 4.19%, 4.78%, and 4.66% respectively [26] Group 4 - The CSI Dividend Index's total cash dividend for 2024 exceeded 920 billion yuan, setting a new historical high with a payout ratio of over 36% [20][21] - The index includes 100 constituent stocks, with China Shenhua distributing over 449 billion yuan [22][23] - The dividend distribution is part of a broader trend of increasing cash dividends among listed companies [20][21]

Core Viewpoint - Hubei Jichuan Pharmaceutical Co., Ltd. announced a cash dividend of 2.09 RMB per share as part of its 2024 annual profit distribution plan, with the record date set for June 27, 2025 [1][2] Company Announcements - The company reported a total market capitalization of 26.702 billion RMB, ranking 7th in the traditional Chinese medicine sector and 566th among all A-shares [1] - The cash dividend distribution will total approximately 1.921 billion RMB, based on 919,349,675 shares [1] - The offer price for the company's buyback will be adjusted from 48 RMB to 45.92 RMB per share, effective June 30, 2025 [2][3] - The adjusted offer price for the share buyback is set at 24.85 RMB per share due to the annual profit distribution [1][3] Dividend Taxation - For individual shareholders holding shares for over one year, the dividend income is exempt from personal income tax, resulting in a net cash dividend of 2.09 RMB per share [1] - For qualified foreign institutional investors (QFII), a 10% corporate income tax will be withheld, leading to a net cash dividend of 1.881 RMB per share [1] - Other institutional investors are responsible for their own tax payments, receiving a net cash dividend of 2.09 RMB per share [1]

Core Viewpoint - The company has announced a differentiated cash dividend distribution plan for the fiscal year 2024, with a cash dividend of 2.09 CNY per share, and adjustments to the share repurchase offer price due to this distribution [1][2]. Summary by Sections Dividend Distribution Plan - The cash dividend distribution plan was approved at the annual shareholders' meeting on May 16, 2025, with a total cash dividend payout of approximately 1.92 billion CNY based on a total share capital of 921,704,160 shares, after deducting shares in the repurchase account and restricted shares [1][2]. Adjustment of Offer Price - The offer price for the company's share repurchase will be adjusted from 26.93 CNY per share to 24.85 CNY per share, effective from June 30, 2025, due to the implementation of the 2024 annual equity distribution [1]. Calculation of Ex-Dividend Price - The ex-dividend reference price will be calculated using the formula: (previous closing price - cash dividend) / (1 + change in circulating shares ratio). The cash dividend per share, after adjustments, is approximately 2.08 CNY [2]. Relevant Dates - Key dates for the dividend distribution include: - Equity registration date: June 27, 2025 - Last trading day: June 30, 2025 - Ex-dividend date: June 30, 2025 [2]. Implementation of Distribution - The cash dividends for shareholders of unrestricted circulating shares will be distributed through the China Securities Depository and Clearing Corporation Limited, Shanghai Branch. Shareholders who have designated trading can receive their cash dividends on the distribution date [2]. Taxation on Dividends - For individual shareholders holding shares for over one year, the cash dividend of 2.09 CNY per share is exempt from personal income tax. For those holding shares for less than one year, tax will be withheld upon the sale of shares [4][6]. - For qualified foreign institutional investors (QFII), a 10% withholding tax will apply, resulting in a net cash dividend of approximately 1.881 CNY per share [6]. Contact Information - For inquiries regarding the equity distribution, shareholders can contact the company's securities affairs department at the provided phone number and email [6].

证券代码： 600566 证券简称： 济川药业 公告编号： 2025-047 湖北济川药业股份有限公司 (一) 鉴于公司实施权益分派，权益分派完成后，本次要约收购的要约收 购价格将相应调整，由 26.93 元/股拟调整为 24.85 元/股。 (二) 对于 2025 年 6 月 27 日（本次权益分派股权登记日）前及当日申报 预受要约的股东，其申报仍按调整前的要约价格 26.93 元/股执行；预受要约股 东将在要约有效期结束后，根据已预受要约且成功被收购人收购的股份数量按照 调整后的要约收购价格 24.85 元/股取得对应款项。对于 2025 年 6 月 30 日起申 报预受要约的股东，其申报按调整后的要约价格 24.85 元/股执行；预受要约股 东将在要约有效期结束后，根据已预受要约且成功被收购人收购的股份数量按照 调整后的要约收购价格 24.85 元/股取得对应款项。 (三) 对于 2025 年 6 月 27 日前、6 月 27 日以及 6 月 30 日起预受要约的股 东，本次要约收购的收购款项支付及股份交割均将在要约收购期结束后统一进行。 (四) 此次要约收购价格调整前后，本次要约收购主体及接受本次要约 ...

证券代码： 600566 证券简称： 济川药业 公告编号： 2025-046 湖北济川药业股份有限公司 关于 2024 年年度权益分派实施后调整回购价格上限的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、 回购股份基本情况 三、 回购价格上限的调整 本次回购股份价格上限由不超过人民币 48 元/股（含）调整为不超过人民币 45.92 元/股（含），具体的价格调整公式如下： 调整后的回购股份价格上限=（调整前的回购股份价格上限-每股现金红利） ÷（1+流通股份变动比例） 每股现金红利=（参与分配的股本总数×实际分派的每股现金红利） ÷总股 本=（919,349,675×2.09）÷921,704,160≈2.08 元/股 根据公司 2024 年度利润分配方案，公司本次权益分派仅进行现金红利分配， 不涉及送股和转增股本，因此，公司流通股不会发生变化，流通股份变动比例为 0。 综上，调整后的回购股份价格上限=（48-2.08）÷（1+0）≈45.92 元/股。 湖北济川药业股份有限公司（以下简称"公司"） ...

重山里 北京植德律师事务所 关于 湖北济川药业股份有限公司 差异化分红事项的 法律意见书 植德(证)字[2025]0023-1 号 二〇二五年六月 北京植德律师事务所 Merits & Tree Law Offices 北京市东城区东直门南大街 1 号来福士中心办公楼 12 层 邮编： 100007 12th Floor, Raffles City Beijing Office Tower, No.1 Dongzhimen South Street, Dongcheng District, Beijing 100007 P.R.C 电话(Tel):010-56500900 传真(Fax):010-56500999 www.meritsandtree.com 北京植德律师事务所 关于 湖北济川药业股份有限公司 差异化分红事项的 本法律意见书仅就本次差异化分红所涉及到的法律问题发表法律意见,并不 对有关会计、审计、验资等专业事项和报告发表意见。本法律意见书中对有关审 计报告、验资报告中某些数据和结论的引述,并不意味着本所对这些数据、结论 的真实性和准确性做出任何明示或默示的保证。对于该等数据、报告的内容,本 所并 ...

湖北济川药业股份有限公司2024年年度权益分派实施公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 证券代码：600566 证券简称：济川药业 公告编号：2025-045 每股分配比例 A 股每股现金红利2.09元 相关日期 | 股份类别 | 股权登记日 | 最后交易日 | 除权（息）日 | 现金红利发放日 | | --- | --- | --- | --- | --- | | Ａ股 | 2025/6/27 | － | 2025/6/30 | 2025/6/30 | 一、 通过分配方案的股东大会届次和日期 本次利润分配方案经公司2025 年 5 月 16 日的2024年年度股东大会审议通过。 二、 分配方案 截至股权登记日下午上海证券交易所收市后，在中国证券登记结算有限责任 公司上海分公司（以下简称"中国结算上海分公司"）登记在册的本公司全体股东。 根据《公司法》《证券法》《上市公司股份回购规则》《上海证券交易所上市公 司自律监管指引第 7 号--回购股份》等相关规定，上市公司回购专用账户中的股 份以及拟回 ...

Investment Rating - The report initiates coverage with a "Buy" rating for the company [10][11]. Core Insights - The company focuses on the production and sales of pediatric, respiratory, digestive, gynecological, and other pharmaceutical products, with key products including Pudilan Anti-inflammatory Oral Liquid and Pediatric Chiqiao Qingre Granules. The company is also advancing its industrial transformation and upgrading, continuously introducing high-quality BD products since 2021 to empower external expansion and lay a foundation for long-term development [3][7]. Revenue and Profitability - The company's revenue grew from 7.208 billion to 9.655 billion from 2018 to 2023, with a CAGR of 6.02%. The net profit attributable to the parent company increased from 1.688 billion to 2.823 billion during the same period, with a CAGR of 10.83%. In 2024, the company expects revenue of 8.017 billion, a year-on-year decline of 16.96%, and a net profit of 2.532 billion, down 10.32% year-on-year [27][28]. Product Matrix - The company’s core products, Pudilan Anti-inflammatory Oral Liquid and Pediatric Chiqiao Qingre Granules, account for over 75% of total revenue, ensuring stable income. Secondary products include Protein Succinyl Iron Oral Solution, Digestive Health Oral Solution, and Huanglong Cough Granules, which are expected to contribute additional revenue in the medium to long term [8][32]. BD Strategy - Since 2022, the company has implemented stock incentive plans and aims to introduce at least four BD products annually, continuously expanding its new drug pipeline. The first batch of products includes long-acting anti-influenza drugs, oral psoriasis medications, and long-acting growth hormones, which are expected to provide sustained growth momentum [9][38]. Key Product Performance - Pudilan Anti-inflammatory Oral Liquid has become a top product in the market despite exiting provincial medical insurance lists, thanks to retail market expansion and unique dosage forms. Pediatric Chiqiao Qingre Granules, a newly developed syrup form, has also been successfully included in medical insurance, contributing to revenue recovery [43][51]. Financial Forecast - The company forecasts revenues of 7.578 billion, 8.074 billion, and 8.707 billion for 2025-2027, with net profits of 2.257 billion, 2.494 billion, and 2.733 billion respectively, corresponding to EPS of 2.45, 2.71, and 2.97 [10].

New Stock Offerings - Jichuan Pharmaceutical (600566) has a tender offer period from June 18, 2025, to July 17, 2025[1] - ST Yazhen (603389) has a tender offer period from June 10, 2025, to July 9, 2025[1] Delisting and Trading Reminders - ST Gongzhi (000584) will enter the delisting arrangement period starting June 20, 2025[1] - ST Jiuyou (600462) will enter the delisting arrangement period starting June 24, 2025[1] - Haiyue (600387) has 12 trading days remaining until the last trading day[1] - Renle (002336) has 11 trading days remaining until the last trading day[1] - Longyu (603003) has 8 trading days remaining until the last trading day[1] - Pengbo (600804) has 8 trading days remaining until the last trading day[1] - Longjin (002750) has 6 trading days remaining until the last trading day[1] Market Volatility - Lianhua Technology (002250) reported severe abnormal fluctuations[1] - ST Kailin (002425) and ST Xuefa (002485) also reported abnormal fluctuations[2]